Back to top

Image: Bigstock

Bristol-Myers Squibb Company

Read MoreHide Full Article

Bristol-Myers’ key products – Opdivo, Orencia, Eliquis and Sprycel – should continue to fuel the company’s top line. Meanwhile, Bristol-Myers is working on expanding the label of Opdivo which should boost performance further. The EC approved Opdivo as a monotherapy for the treatment of SCCHN in adults. The company is also looking to diversify its portfolio with the development of BMS-986036 for NASH. The increase in 2017 guidance was also encouraging. Estimates have been static ahead of Q2 results. Opdivo is currently facing competitive challenges in the U.S. With the FDA approving Merck’s Keytruda, for the first-line treatment of metastatic nonsquamous NSCLC, the company is expected to see further loss of market share. Moreover, shares of the company have underperformed the industry in the last twelve months.


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Bristol Myers Squibb Company (BMY) - free report >>

Published in